Gsk (GLAXF) Income from Continuing Operations (2009 - 2026)

Gsk's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 3301688900.49 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 7.26% year-over-year to 3301688900.49; the TTM figure through Mar 2026 stood at 12618375243.24 (up 31.15% YoY), while the FY2025 annual figure was 8292111502.56, up 119.82% from the prior year.
• Income from Continuing Operations was 3301688900.49 for Q1 2026 at Gsk, up from 2742802701.24 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 5771356267.04 in Q4 2023 to a low of 81855910.5 in Q3 2024.
• Historically, Income from Continuing Operations has averaged 2851671390.19 across 5 years, with a median of 2789288468.13 in 2023.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 96.84% in 2024, then surged 4462.94% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 4336316003.25 in 2022, then soared by 33.09% to 5771356267.04 in 2023, then dropped by 24.92% to 4333102209.79 in 2024, then sank by 36.7% to 2742802701.24 in 2025, then climbed by 20.38% to 3301688900.49 in 2026.
• The last three Income from Continuing Operations figures came in at 3301688900.49 (Q1 2026), 2742802701.24 (Q4 2025), and 3735034424.74 (Q3 2025), per Business Quant data.